Evidence map›Paper›PMID 35534540›Full record

ArticleOncogene2022

Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.

Patience Odeniyide, Marielle E Yohe, Kai Pollard, Angelina V Vaseva, Ana Calizo, Lindy Zhang, Fausto J Rodriguez, John M Gross, Amy N Allen, Xiaolin Wan and 5 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Patience OdeniyideDivision of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-9783-1657
Marielle E YohePediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Kai PollardDivision of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Angelina V VasevaThe Greehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Ana CalizoDivision of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lindy ZhangDivision of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Fausto J RodriguezDepartment of Laboratory Medicine and Pathology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-8662-1219
John M GrossDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Amy N AllenDivision of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Xiaolin WanPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Romel SomwarDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Karisa C SchreckDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-7181-3269
Linda KesslerKura Oncology, San Diego, CA, USA.
Jiawan WangDivision of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Christine A PratilasDivision of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. cpratil1@jhmi.edu.ORCID http://orcid.org/0000-0002-7116-0605

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
Targeting RAS in Pediatric CancerZIABC011892 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI YOHE, MARIELLE · 2019 to 2025
$2.3M
Improving Therapeutic Approaches for RAS-driven RhabdomyosarcomaR37CA262657 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Angelina V Vaseva · 2022 to 2026
$1.8M
NCI NIH HHS P50 CA211015NCI NIH HHS R37 CA262657
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35534540
PMCPMC9122821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.